Wikipedia -WSS

Wikipedia

author：knowledge 2025-08-12 13:36:32 - browse：28148

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Stanford president to resign after investigation of research

WSS

Couple fighting to bring baby home from Mexico are finally reunited

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Merck to acquire Harpoon Therapeutics for $680 million

India sets sights on home

Study suggests new cause of Down syndrome: cells linked to aging

hotspot

Wikipedia

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The kidney, in all its complexity, is captured in a new atlas

How to save PrEP access — and even expand it

Medicare Advantage overpayments discussion gets experts fired up

What does generative AI mean for health care? We asked experts

Does Paxlovid work in people vaccinated against Covid

United colonoscopy coverage change 'may cost lives,' doctors say

'Reaching a detente': STAT's Helen Branswell on covering Covid

Drug repurposing or repositioning? The language matters

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

leisure time

Lindsay Lohan welcomes 1st child with husband Bader Shammas

In shift, Texas to cover initial consult for Afghan baby's gene therapy

New warning issued for rebooking air travel after delays, cancellations

Resistance to cancer drugs: A new genetic explanation

Hospital chaplains balance Covid safety with patients’ spiritual needs

Arena BioWorks launches in Cambridge to speed drug discovery

focus

leisure time

knowledge

hotspot